Ameritas Investment Partners’s Acrivon Therapeutics ACRV Stock Holding History

Ameritas Investment Partners’s Portfolio ACRV Stock Details ACRV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-695	Closed	-$1.41K	–	3200
2025 Q1	$1.41K	Hold	695	–	–	﹤0.01%	3090
2024 Q4	$4.18K	Hold	695	–	–	﹤0.01%	3050
2024 Q3	$4.87K	Hold	695	–	–	﹤0.01%	3040
2024 Q2	$4.03K	Hold	695	–	–	﹤0.01%	3052
2024 Q1	$4.97K	Hold	695	–	–	﹤0.01%	2950
2023 Q4	$3.42K	Hold	695	–	–	﹤0.01%	3021
2023 Q3	$6.64K	Hold	695	–	–	﹤0.01%	2936
2023 Q2	$9.01K	Hold	695	–	–	﹤0.01%	2940
2023 Q1	$8.82K	Buy	+695	New	+$11.7K	﹤0.01%	2761

Other funds holding ACRV

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

SCV

Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Ameritas Investment Partners's ACRV Position: Q2 2025 in Review

Ameritas Investment Partners sold out of Acrivon Therapeutics (ACRV) in Q2 2025, closing a stake of 695 shares — an estimated $1.41K sold.

Ameritas Investment Partners first reported a position in ACRV in Q1 2023 and held it in 9 quarters. The position peaked at $9.01K in Q2 2023. 53 funds tracked by Wall St. Rank hold ACRV as of Q2 2025.

Ameritas Investment Partners reported no remaining Acrivon Therapeutics position as of Q2 2025 after selling out during the quarter.
Ameritas Investment Partners sold 695 Acrivon Therapeutics shares in Q2 2025, an estimated $1.41K.
Ameritas Investment Partners first reported a position in Acrivon Therapeutics in Q1 2023 and held it in 9 quarters.
Ameritas Investment Partners's Acrivon Therapeutics position peaked at $9.01K in Q2 2023.
53 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q2 2025.

Based on Ameritas Investment Partners's 13F filing for Q2 2025, filed 12 Aug 2025.